Causes of Hypofibrinogenemia in Cancer Patients
The primary cause of hypofibrinogenemia in cancer patients is disseminated intravascular coagulation (DIC), which results from activation of the coagulation system by the malignancy itself, leading to consumption of fibrinogen through excess thrombin generation and subsequent fibrinolysis. 1
Primary Mechanism: Cancer-Associated DIC
Coagulation activation by malignancy is the fundamental driver of hypofibrinogenemia in cancer patients. The cancer directly activates the coagulation system, triggering continuous thrombin generation that consumes fibrinogen faster than it can be produced 1. This process occurs across multiple cancer types but is particularly prominent in:
- Acute promyelocytic leukemia (APL) - where DIC with hypofibrinogenemia is a hallmark complication and major cause of induction mortality 1
- Solid tumors - especially prostate, pancreatic, gastric, and lung cancers 2, 3
- Hematologic malignancies - including other acute leukemias and lymphomas 4
Secondary Mechanisms Contributing to Hypofibrinogenemia
Excessive Fibrinolysis (Hyperfibrinolytic DIC)
Cancer cells can produce urokinase-type plasminogen activator, leading to a particularly severe variant of DIC with excessive fibrinolysis (XFL) 2, 3. This mechanism:
- Causes rapid fibrinogen consumption beyond typical DIC
- Results in severe bleeding tendency with purpura and hemorrhage
- Is characterized by persistently low α2-antiplasmin levels and elevated plasmin-antiplasmin complex 2
- Occurs most notably in prostate cancer but can complicate other malignancies 3
Decreased Hepatic Production
Liver failure from metastatic disease or hepatic dysfunction can cause decreased fibrinogen production and function 1. This is particularly relevant in patients with:
- Extensive hepatic metastases
- Cancer-related liver impairment
- Advanced disease with poor organ function 1
Paraprotein Interference
In multiple myeloma and other plasma cell disorders, monoclonal proteins can directly interfere with fibrinogen through:
- Binding to fibrinogen molecules, accelerating removal 5
- Leukocyte-mediated fibrinogen clearance triggered by paraprotein-fibrinogen complexes 5
- This mechanism is rare but can cause severe hypofibrinogenemia with fibrinogen levels below detection limits 5
Chemotherapy-Related Causes
L-asparaginase therapy in acute lymphoblastic leukemia causes hypofibrinogenemia through:
- Reduced hepatic protein synthesis, including fibrinogen 6
- Fibrinogen levels <50 mg/dL occur in approximately 13% of patients 6
- Paradoxically increases thrombosis risk despite low fibrinogen (relative risk of 10 for thrombosis when fibrinogen <50 mg/dL) 6
Steroid-containing chemotherapy regimens can cause acquired hypofibrinogenemia in lymphoblastic leukemias:
- Occurs repeatedly and promptly with steroid administration 4
- Independent of steroid type (prednisolone, dexamethasone, methylprednisolone) or route 4
- Requires monitoring during first course of therapy 4
Clinical Recognition Algorithm
The ISTH-SSC guidelines emphasize that physicians must recognize variations in laboratory parameters due to the underlying malignancy 1:
Monitor fibrinogen trends - A decreasing fibrinogen level is more significant than absolute values, as some cancers initially cause elevated levels 1
Look for subclinical DIC - Hypofibrinogenemia may be the only laboratory abnormality, as PT/PTT are prolonged in only ~50% of cancer-associated DIC cases 1
Check D-dimers and fibrin degradation products - Elevated levels with low fibrinogen confirm consumptive coagulopathy 1
Assess for excessive fibrinolysis - Low α2-antiplasmin and elevated plasmin-antiplasmin complex indicate hyperfibrinolytic DIC requiring different management 2
Critical Pitfall
A "normal" fibrinogen level in a cancer patient may actually represent significant DIC if the baseline was markedly elevated due to the malignancy 1. A 30% or higher drop in fibrinogen should be considered diagnostic of subclinical DIC even if the absolute value remains in the normal range 1.